KPTI News and Press, Karyopharm Therapeutics Inc. From 01/04/21

Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020 compared to the 16% in the SPDR S&P 500 Trust ETF (SPY). The outlook is underpinned by uncertainty...

Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference PR Newswire NEWTON, Mass. , Jan. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today...

Antengene submits a New Drug Application ((NDA)) in South Korea for ATG-010 (selinexor, XPOVIO) in combination with low dose dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma (rrMM) and for ATG-010 as monotherapy for treatment of relaps...

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL PR Newswire SHANGHAI and HONG KONG , Jan. 3, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedi...

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy --Oral XPOVIO® Approval as Combination Therapy in Patients with Multi...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI). On February 22, 2019, the Federal Dr...

Karyopharm Therapeutics (KPTI) announced that FDA has approved XPOVIO in combination with bortezomib and dexamethasone for patients with multiple myeloma after at least one prior therapy.XPOVIO, a first-in-class, oral Selective Inhibitor of Nuclear Export medicine was earlier approved for adu...

Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy -- Oral XPOVIO Now Available as a Treatment Option for Patients with Multiple Myeloma As Early as First Relapse; Significantly Expands...

Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma NEWTON, Mass. , Dec. 11, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (N...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this event. For further details see: Karyopharm Therapeutics (KPTI) Presents At American Society of Hematology - Slideshow